Business Of Biotech

What's Next For COVID Vaccines With Tonix Pharmaceuticals' Seth Lederman, M.D.

Matt Pillar

We love to hear from our listeners. Send us a message.

As COVID-19 cases climb yet again,  the Business of Biotech catches up with Tonix Pharmaceuticals CEO Seth Lederman, M.D. for a conversation on his company's multi-pronged strategy to advance vaccine and therapeutic candidates to address the disease and its variants. In addition to sharing on his journey from academia to industry, Dr. Lederman discusses his company's approach to grabbing its share of the highly competitive, and highly lucrative, vaccine market.

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.

Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com

Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/


People on this episode

Podcasts we love

Check out these other fine podcasts recommended by us, not an algorithm.